Literature DB >> 30859313

The Economic Effect of Early Management in Patients with Early Chronic Obstructive Pulmonary Disease: Results from a Population-Based Nationwide Survey.

Young Seok Lee1, Kyung Hoon Min1, Chin Kook Rhee2, Yong Hyun Kim3, Seong Yong Lim4, Soo-Jung Um5, Chang-Hoon Lee6, Ki-Suck Jung7, Kwang Ha Yoo8.   

Abstract

PURPOSE: The economic effect of regular follow-up and early management in patients with early chronic obstructive pulmonary disease (COPD) has not yet been clarified. Therefore, this study aimed to estimate the economic effect of regular follow-up and early management in these patients.
METHODS: Patients with early COPD were identified from the Korea National Health and Nutrition Examination Survey. We analyzed medical utilization and cost for 2 years without any missing data by using the Korean National Health Insurance data. Patients with routine healthcare maintenance were defined as, after diagnosis, those with regular visits to the hospital and receiving early management of COPD.
RESULTS: Among 1204 patients with early COPD, the patients who were classified as the group with routine healthcare maintenance (69/146; 47.3%) and the group with intermittent healthcare user (79/1058; 7.5%) visited to hospital for the next 2 years. The patients with routine healthcare maintenance had lower cost of inpatient service and frequencies of emergency room (ER) visit and intensive care unit (ICU) admission than intermittent healthcare users (cost of inpatient service, $4595 vs. $4953 per person; ER visit, 7.2 vs. 11.5; ICU admission, 4.3 vs. 7.7). Even in patients with COPD and FEV1 ≥ 80, early intervention through follow-up reduced the cost of inpatient service because these patients could have had less severe acute exacerbations than intermittent healthcare users.
CONCLUSION: Patients with early COPD, even those with FEV1 ≥ 80, need regular follow-up for early management and disease control as well as for reducing the socioeconomic burden of the disease.

Entities:  

Keywords:  Chronic obstructive pulmonary disease; Early intervention; Economics; Korea

Mesh:

Year:  2019        PMID: 30859313     DOI: 10.1007/s00408-019-00208-5

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  44 in total

1.  Standardisation of spirometry.

Authors:  M R Miller; J Hankinson; V Brusasco; F Burgos; R Casaburi; A Coates; R Crapo; P Enright; C P M van der Grinten; P Gustafsson; R Jensen; D C Johnson; N MacIntyre; R McKay; D Navajas; O F Pedersen; R Pellegrino; G Viegi; J Wanger
Journal:  Eur Respir J       Date:  2005-08       Impact factor: 16.671

2.  Lung-Function Trajectories Leading to Chronic Obstructive Pulmonary Disease.

Authors:  Peter Lange; Bartolome Celli; Alvar Agustí; Gorm Boje Jensen; Miguel Divo; Rosa Faner; Stefano Guerra; Jacob Louis Marott; Fernando D Martinez; Pablo Martinez-Camblor; Paula Meek; Caroline A Owen; Hans Petersen; Victor Pinto-Plata; Peter Schnohr; Akshay Sood; Joan B Soriano; Yohannes Tesfaigzi; Jørgen Vestbo
Journal:  N Engl J Med       Date:  2015-07-09       Impact factor: 91.245

3.  Susceptibility to exacerbation in chronic obstructive pulmonary disease.

Authors:  John R Hurst; Jørgen Vestbo; Antonio Anzueto; Nicholas Locantore; Hana Müllerova; Ruth Tal-Singer; Bruce Miller; David A Lomas; Alvar Agusti; William Macnee; Peter Calverley; Stephen Rennard; Emiel F M Wouters; Jadwiga A Wedzicha
Journal:  N Engl J Med       Date:  2010-09-16       Impact factor: 91.245

4.  Clinical and Radiologic Disease in Smokers With Normal Spirometry.

Authors:  Elizabeth A Regan; David A Lynch; Douglas Curran-Everett; Jeffrey L Curtis; John H M Austin; Philippe A Grenier; Hans-Ulrich Kauczor; William C Bailey; Dawn L DeMeo; Richard H Casaburi; Paul Friedman; Edwin J R Van Beek; John E Hokanson; Russell P Bowler; Terri H Beaty; George R Washko; MeiLan K Han; Victor Kim; Song Soo Kim; Kunihiro Yagihashi; Lacey Washington; Charlene E McEvoy; Clint Tanner; David M Mannino; Barry J Make; Edwin K Silverman; James D Crapo
Journal:  JAMA Intern Med       Date:  2015-09       Impact factor: 21.873

Review 5.  Should mild COPD be treated? Evidence for early pharmacological intervention.

Authors:  Amany F Elbehairy; Katherine A Webb; J Alberto Neder; J Alberto Neder; Denis E O'Donnell
Journal:  Drugs       Date:  2013-12       Impact factor: 9.546

6.  Trends in the prevalence of obstructive and restrictive lung function among adults in the United States: findings from the National Health and Nutrition Examination surveys from 1988-1994 to 2007-2010.

Authors:  Earl S Ford; David M Mannino; Anne G Wheaton; Wayne H Giles; Letitia Presley-Cantrell; Janet B Croft
Journal:  Chest       Date:  2013-05       Impact factor: 9.410

Review 7.  Smoking Cessation in Chronic Obstructive Pulmonary Disease.

Authors:  Donald P Tashkin
Journal:  Semin Respir Crit Care Med       Date:  2015-08-03       Impact factor: 3.119

Review 8.  The Role of Bronchodilators in Preventing Exacerbations of Chronic Obstructive Pulmonary Disease.

Authors:  Kai M Beeh
Journal:  Tuberc Respir Dis (Seoul)       Date:  2016-10-05

9.  Natural course of early COPD.

Authors:  Chin Kook Rhee; Kyungjoo Kim; Hyoung Kyu Yoon; Jee-Ae Kim; Sang Hyun Kim; Sang Haak Lee; Yong Bum Park; Ki-Suck Jung; Kwang Ha Yoo; Yong Il Hwang
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2017-02-20

Review 10.  Exacerbations of COPD.

Authors:  Ian D Pavord; Paul W Jones; Pierre-Régis Burgel; Klaus F Rabe
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-02-19
View more
  2 in total

Review 1.  The current status of chronic obstructive pulmonary disease awareness, treatments, and plans for improvement in South Korea: a narrative review.

Authors:  Yong Bum Park; Kwang Ha Yoo
Journal:  J Thorac Dis       Date:  2021-06       Impact factor: 2.895

2.  Influence of Baduanjin on lung function, exercise capacity, and quality of life in patients with mild chronic obstructive pulmonary disease.

Authors:  Yang Yang; Keling Chen; Wenjun Tang; Xiaohong Xie; Wei Xiao; Jing Xiao; Xialing Luo; Wujun Wang
Journal:  Medicine (Baltimore)       Date:  2020-09-11       Impact factor: 1.889

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.